Correspondence 0001193125-23-147031 from HilleVax, Inc. (HLVX) (CIK 0001888012)
HilleVax, Inc. (HLVX) (CIK 0001888012)
Date: May 17, 2023 · CIK: 0001888012 · Accession: 0001193125-23-147031
AI Filing Summary & Sentiment
File numbers found in text: 333-271892
Letter
HilleVax, Inc.
75 State Street, Suite 100 – #9995
Boston, MA 02109
May 17, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: HilleVax, Inc.
Registration Statement on Form S-3
File No. 333-271892
To the addressees set forth above:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of HilleVax, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 19, 2023, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.
Very truly yours,
HILLEVAX, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP HilleVax, Inc. 75 State Street, Suite 100 – #9995 Boston, MA 02109 May 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: HilleVax, Inc. Registration Statement on Form S-3 File No. 333-271892 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of HilleVax, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on May 19, 2023, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter. Very truly yours, HILLEVAX, INC. By: /s/ Robert Hershberg, M.D., Ph.D. Robert Hershberg, M.D., Ph.D. President and Chief Executive Officer cc: Paul Bavier, HilleVax, Inc. Cheston J. Larson, Latham & Watkins LLP Matthew T. Bush, Latham & Watkins LLP